FDA Approves Talzenna to Treat BRCA+ Metastatic Breast Cancer

Options
Moderators
Moderators Member Posts: 25,912
edited October 2018 in Genetic Testing

FDA Approves Talzenna to Treat Metastatic Breast Cancer in Women With BRCA Mutations
October 17, 2018

The FDA has approved Talzenna (chemical name: talazoparib) to treat locally advanced or metastatic HER2-negative breast cancer in women with an inherited BRCA1 or BRCA2 mutation. Read more...

Categories